Weekly Roundup -
February 4, 2026
Smart. Strategic. Essential.
Unmatched Healthcare Insights from ºìÁì½í¹Ï±¨,
Leavitt Partners & Wakely.
Featured:
Medicaid Changes in the OBBBA and Implications for the Marketplace and Individual Market in 2027
READ BRIEFTrending: In Focus
ºìÁì½í¹Ï±¨â€™s Take on 2026 ACA Marketplace Open Enrollment Snapshot
On January 28, 2026, the Centers for Medicaid & Medicare Services (CMS)Ìýreleased its secondÌý of 2026 Affordable Care Act (ACA) Marketplace Open Enrollment (OE) activity. While this update is not a final accounting of enrollment activity, it is likely to be the last OE federal data release for some time and offers an early look at how enrollment trends are shifting in the wake of expired enhanced premium tax credits and new eligibility standards under the 2025 budget reconciliation act (P.L. 119-21, OBBBA).Ìý
In this article, ºìÁì½í¹Ï±¨ (ºìÁì½í¹Ï±¨)Ìýand Wakely, an ºìÁì½í¹Ï±¨ company,Ìýhighlight findings from their analysis of the 2026ÌýOE activity andÌýcompareÌýthis activityÌýwith 2025 data.ÌýThis analysis builds on the findings inÌýtheir January 2026 analysisÌý()Ìýand will provide important context for theÌý2027 plan year.Ìý
Overall Enrollment TrendsÌý
CMS reports that 2026 plan selections decreased by 5 percent from 2025, with enrollment declining across both new and returning consumers. New sign-ups dropped by 14 percent and renewals fell by 3 percent (Table 1). State-based Marketplace (SBM) enrollment dipped modestly, though many SBMs were still enrolling consumers in late January.Ìý
Table 1. Comparison of 2026 and 2025 Open EnrollmentÌý
| Ìý | 2026Ìý | 2025Ìý | Net ChangeÌý |
| TotalÌý | 22,973,219Ìý | 24,166,491Ìý | (1,193,272)Ìý |
| New ConsumersÌý | 3,382,189Ìý | 3,938,907Ìý | (556,718)Ìý |
| Returning ConsumersÌý | 19,591,030Ìý | 20,227,584Ìý | (636,554)Ìý |
Ìý
Variation Across State-Based and Federally Facilitated MarketplacesÌý
Enrollment patterns variedÌýsubstantially acrossÌýstates.Ìý
SBMs:Ìý
- New MexicoÌýsaw theÌýlargestÌýyear-over-yearÌýincreaseÌý(14%), attributed toÌýstate-funded subsidiesÌýdesigned toÌýoffset the loss ofÌýenhanced premium tax credits (ePTCs).Ìý
- GeorgiaÌýexperienced aÌý14Ìýpercent decline,ÌýtheÌýsteepest drop amongÌýSBMs.Ìý
Federally Facilitated Marketplace (FFM)ÌýStates:Ìý
- Overall, FFM enrollment fellÌý5Ìýpercent.Ìý
- Texas ledÌýFFM statesÌýwith aÌý5Ìýpercent increase inÌýplan selections.Ìý
- Ohio and North Carolina experiencedÌýsubstantial enrollment declines,Ìý20ÌýpercentÌýandÌý22ÌýpercentÌýrespectively.Ìý
What This Tells Us—andÌýWhatÌýItÌýDoesn’tÌýTell UsÌýYetÌý
FFM data are as of January 15, 2026,Ìýand measure plan selections after the OE period ended.ÌýWithin the FFM, state-by-state enrollment activity varied significantly.ÌýSome of this variation is surprising and not readily explainable from the available data and will be a focus of futureÌýºìÁì½í¹Ï±¨Ìýand Wakely analyses.Ìý
The data include neither effectuated enrollment nor paid enrollment—data which will be key to fully understanding 2026 enrollment trends and the impact of changing federal policies, including theÌýePTCÌýexpirationÌýand changing eligibility standards introduced in 2026 as the result of OBBBA.Ìý
ÌýsuggestÌýsignificantly higher cancellation and disenrollment rates than inÌýprevious years.Ìý
SBMs are sharing that they expectÌýsubstantial affordability-driven voluntary and nonpayment terminations over the first half of 2026.Ìý
Monitoring paid enrollments, attrition, and grace period dynamics, including retro-terminations, will be key to understanding market dynamics and 2027 pricing.Ìý
Connect with UsÌý
ºìÁì½í¹Ï±¨ and Wakley experts have considerable experience working with states, insurers, and federal policymakers withÌýjurisdictionÌýover the Marketplace. We work with these entities to inform, analyze, andÌýshapeÌýfederal policies and conduct impact analyses on pricing, enrollment, administration, and operations. ºìÁì½í¹Ï±¨ also provides strategic and project management support for the implementation of finalized policies.Ìý
Please contactÌýMichael Cohen,ÌýTaylor Gehrke, orÌýZachary Sherman with questions, follow-up, or if you would like expertÌýassistanceÌýexploring any of the issues discussed in this post.
Congress Advances FY 2026 HHS Appropriations Bill with Health Extenders and PBM Reforms
On February 3, 2026, Congress finalized federal funding for fiscal year (FY) 2026, with the House passing the Consolidated Appropriations Act (CAA), 2026, with a vote of 217-214, following Senate approval last week. The president signed the CAA () shortly thereafter. The law provides full-year appropriations for the Departments of Health and Human Services (HHS), Housing and Urban Development, Labor, and several other departments.Ìý
This year’s HHS funding bill is notable not only for what it includes, but also for what it omits. It restores or maintains funding for key public health and research agencies previously proposed for elimination in the president’s FY 2026 , extends several healthcare programs, and contains a significant package of pharmacy benefit manager (PBM) reforms. All of this activity comes as the Administration Ìýnew grant programs and policy effortsÌýrelated toÌýitsÌýsignature priorities.Ìý
In this article, we review the major funding and policies approved in the HHS spending bill. We also address key considerations for healthcare organizations as they anticipate downstream funding and policy developments and develop advocacy initiatives for federal FY 2027 bills.Ìý
HHS Funding Levels and DirectionÌý
The bill provides $116.8 billion for HHS, an increase of $210 million over FY 2025, and rejects large-scale structural reorganizations proposed in the president’s FY 2026 budget. This provision preserves funding for the Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), Health Resources & Services Administration (HRSA), and the Substance Abuse and Mental Health Services Administration (SAMHSA)Ìý
Table 1. HHS AgencyÌýFundingÌýHighlights, FY 2026Ìý
| AgencyÌýÌý | FY 2026 FundingÌýÌý | (+/-) ComparedÌýwithÌýFY 2025Ìý |
| Administration for Strategic Preparedness and Response (ASPR)Ìý | $3.7ÌýbillionÌý | +$58ÌýmillionÌýÌý |
| CDCÌý | $9.2 billionÌý | level fundingÌý |
| Centers for MedicareÌý&ÌýMedicaid Services (CMS),Ìýadministrative expensesÌýonlyÌýÌý | $3.7 billionÌý | level fundingÌýÌý |
| ÌýHRSAÌý | $8.9 billionÌý | +$415ÌýmillionÌýÌý |
| National Institutes of Health (NIH)Ìý | $48.7 billionÌýÌý | +$929ÌýmillionÌýÌý |
| SAMHSAÌý | $7.4 billionÌýÌý | +$65ÌýmillionÌýÌý |
Ìý
The bill also extends mandatory funding for community health centers, special diabetes programs, the National Health Service Corps, and Teaching HealthÌýCenterÌýGraduate Medical Education.Ìý
PBM Reforms in the PackageÌý
In one closely watched area of federal policymaking, the FY 2026 package includes a substantial set of PBM-related reforms thatÌýlargely mirrorÌýthe bipartisan package negotiatedÌýbut not enactedÌýin December 2024. These reforms have implications across Medicare Part D, commercial insurance, and employer-sponsored plans.Ìý
The legislationÌýcontainsÌýthe followingÌýPBM reforms:Ìý
- Prohibits PBMs from derivingÌýremunerationÌýlinked to drug prices forÌýMedicare-covered Part D drugsÌý
- Restricts spread pricing in Medicaid,ÌýeliminatingÌýa major driver of PBM revenueÌý
- Requires contractual transparency, mandating that PBMs clearly define pricing terms in agreements with Part D plan sponsorsÌý
- Adds new PBM reporting obligations, including drug price reporting and rebate disclosuresÌý
- Requires 100ÌýpercentÌýpassthrough of rebates in ERISA-regulated plans for new, renewed, or extended contracts beginningÌý30 monthsÌýafter enactmentÌý
- Expands audit rights for plan sponsorsÌý
- Codifies the “any willing pharmacy†requirement for Medicare plan sponsorsÌý
These provisions position 2026 as a consequential year for PBM regulation, increasing transparency, strengthening plan leverage, and heightening HHS oversight.Ìý
Healthcare Extenders and Program ReauthorizationsÌý
The bill includes a broad set of Medicaid, Medicare, and public health program extenders, affecting providers, patients, states, and managed care plans.Ìý
MedicaidÌý
- Postpones reductionsÌýin theÌýDisproportionate Share Hospital (DSH)ÌýallotmentsÌýuntil FY 2028Ìý
- ChangesÌýtheÌýDSH cap calculationÌýtoÌýbroaden which patient costs count toward Medicaid shortfallÌý
- Requires states toÌýdevelop and implement a process toÌýallow certain out-of-state pediatric providers to deliver services withoutÌýadditionalÌýscreening for three yearsÌý
- Removes age limits on Medicaid’s Ticket to Work program, allowing adults older than ageÌý65 toÌýparticipateÌýand requires state compliance by January 1, 2028Ìý
- Establishes new maternity care reporting requirementsÌýfor rural hospitals, with dedicated federal fundingÌýfor hospitalsÌýand states toÌýcomply withÌýthe reportingÌý
MedicareÌý
Congress extends several key programs and payment provisions, including:Ìý
- Telehealth flexibilities through December 31, 2027Ìý
- Incentive payments for participation in eligible alternative payment models through payment year 2028 (for performance year 2026) and applies an adjustment amount of 3.1 percent for 2028Ìý
- Acute Hospital Care at Home waivers through 2030Ìý
- Low-volume and Medicare-dependent hospital payment adjustmentsÌý
- TheÌý1.0 work geographic practice cost index floor used in the calculation of payments under the Medicare physician fee schedule through December 31, 2026Ìý
- Add-on payments for ambulance servicesÌý
- Continuation of Part D coverage for certain antivirals and modifications to hospice payment capsÌý
Behavioral Health PolicyÌý
The appropriations billÌýwasÌýfinalizedÌýas theÌýadministrationÌýÌýnew funding and policy initiativesÌýtoÌýsupport behavioral health, crisis services, workforce expansion, and youth mental health—efforts mirrored in SAMHSA’s increased appropriations.Ìý
SAMHSA’sÌý$7.4 billionÌýbudgetÌýincludes:Ìý
- $1.6 billionÌýfor State Opioid Response grantsÌý
- $1.01 billionÌýfor the Mental Health Block GrantÌý
- $535 million for the 988 Suicide and Crisis LifelineÌý
Considerations for StakeholdersÌý
FederalÌýfunding andÌýpolicy developmentsÌýaffectÌýstate budget dynamics as many states are now releasing 2026–2027 budget proposalsÌýas well as theÌýoperational and growth plans of healthcare organizations and partners.Ìý
A few keyÌýtakeawaysÌýfrom theÌýFY 2026 funding billÌýinclude:Ìý
- Federal appropriations signalÌýcongressional andÌýadministration priorities and haveÌýdownstreamÌýimpact on upcoming rounds of grant cycles, includingÌýSAMSHA and HRSAÌýawards.Ìý
- The approved funding and certain policy extensions provide operational stability and reduce near-term fiscal pressure, such as the further delay of Medicaid DSH cuts. The extra time will allow healthcare entities to prepare for future reductions and plan for financial sustainability.Ìý
- Agency and program funding emphasize oversight, program integrity, andÌýcompliance. In addition,Ìýfraud and program integrityÌýpriorities areÌýwoven intoÌýcertainÌýnewÌýpoliciesÌýand programÌýextensions,ÌýincludingÌýPBM reforms, flexibility for pediatric care across state borders,Ìýand rural maternity cost reporting requirements,Ìýamong others.Ìý
Connect with UsÌý
If you would like deeper analysis or state and stakeholder-specific effects, ºìÁì½í¹Ï±¨â€™sÌýpolicy expertsÌýare available toÌýassist.Ìý
Federal Policy News
Fueled By Weekly Health Intelligence
FDA Opens PreCheck Pilot Applications Ahead of March 1 Deadline
On February 1,Ìýthe Food and Drug Administration (FDA)ÌýÌýit has begun accepting requests from pharmaceutical manufacturers toÌýparticipateÌýin theÌý. The program, which was firstÌýÌýby FDA in August 2025 in response toÌý, aims to increase regulatory predictability and incentivize domestic pharmaceutical manufacturing by streamlining facility assessments for manufacturers constructing new sites in the U.S. The pilot consists of two phases: 1) a “Facility Readiness Phase†that allows for manufacturers to engage with FDA for early technical advice on facility design, construction, and pre-production, and 2) a “Application Submission Phase†that utilizes pre-submission meetings and inspections to expedite resolution of issues and assessments of manufacturing information in a drug application. FDA Commissioner Marty Makary characterized the program as a key incentive to increase the resilience and competitiveness of the U.S. pharmaceutical manufacturing sector. The agency will select facilities for theÌýinitialÌý2026 cohort, with priority consideration given to those producing critical medications for the U.S. market. Interested applicants for the 2026 cohort mustÌýsubmitÌýaÌýÌýrequesting toÌýparticipateÌýby March 1, 2026.Ìý
Executive Order Establishes Great American Recovery Initiative to Address Addiction
On January 29, President Trump signed anÌýÌý(EO), titled, “Addressing Addiction Through the Great American Recovery Initiative,†which is intended toÌýestablishÌýa coordinated federal response to substance use disorders and support addiction recovery. The EO establishes the “White House Great American Recovery Initiative,†which includes a council of agency leaders, to be co-chaired by the Secretary of HHS and the Senior Advisor for Addiction Recovery, with an executive director who will administer the day-to-day operations. It will include leaders of key agencies, including the head of SAMHSA, Director of NIH, Commissioner of FDA, and the Administrator of CMS. The EO directs members of the Initiative to:Ìý
- Recommend next steps to coordinate federal response to the addiction crisis, including aligning programs,ÌýestablishingÌýclearÌýobjectives, and using data to track progress towards theÌýobjectives;Ìý
- Raise awareness of addiction, treatment, and recovery services, including to “foster a culture that celebrates recovery;â€Ìý
- Provide advice to agencies on encouraging relevant grants to include support for recovery, as well as prevention, treatment, and long-term resilience;Ìý
- AdviseÌýstates and other agencies on grant appropriation and allocations which support addiction recovery; andÌý
- Consult with states, tribal nations, and non-governmental organizations on strategies to improve access to treatment and encourage recovery.Ìý
The EO states that the co-chairs may hold public hearings and other convenings to receive expert input. While the EO does not detail specific deadlines or deliverables related to the initiative’s work, HHS Secretary Robert F. Kennedy, Jr. Ìýthe Safety Through Recovery, Engagement, and Evidence-based Treatment and Supports (STREETS) Initiative to direct $100 million in federal funding to “targeted outreach, psychiatric care, medical stabilization and crisis intervention, while connecting Americans experiencing homelessness and addiction to stable housing with a clear focus on long-term recovery and independence.†Secretary Kennedy also announced $10 million toward an Assisted Outpatient Treatment (AOT) grant program.Ìý
CMS Finalizes Rule Closing Medicaid Provider Tax Loophole
On January 29, CMSÌýÌýtheÌý. The rule implements section 71117 of the FY 2025 budget reconciliation law () and seeks to address a “loophole†in the statistical test used to assess whether states may receive a waiver from federal requirements that Medicaid provider taxes be “broad-based and uniform.†CMS estimates that the final rule will save the federal government overÌý$78 billion over the next ten years. In the law, Congress permittedÌýthe Secretary of HHS to provide a transition period of up to three years for states depending on when their waivers were most recently approved. The rule alsoÌýfinalizesÌýthe allowed transition period for states, such that states are afforded, depending on the status of their current waivers, a transition period of at least until the end of calendar year 2026, and up to three years. In the final rule, CMS notes that seven states have existing “loophole waivers†in place, and across those states, there are nine such waivers in place.Ìý
CMS Issues Letter Notifying States of Changes to State Directed Payment Policies
On February 2, 2026, the Centers for Medicare & Medicaid Services (CMS)  an updated letterÌýregardingÌýrestrictions of state directed payments (SDPs) approved under the 2025 budget reconciliation act (P.L 119-21, OBBBA). The letter replaces a September 2025 letter andÌýprovidesÌýupdated guidance on SDPs while the agency goes through a rulemaking process. The letter alsoÌýstatesÌýthat CMS is considering changes to the total payment rate limit for SDPs for other services beyond those highlighted inÌýstatute,ÌýincludingÌýinpatient hospital services, outpatient hospital services, nursing facility services, and qualified practitioner services at an academic medical center.Ìý
Ready to talk about your organization's challenges?
Schedule a ConsultationState Policy News
Arizona
Arizona Medicaid Director to Step Down February 13. The Office of the Governor Katie Hobbs  on February 2, 2026, that Virginia “Ginny†Rountree, Director of the Arizona Health Care Cost Containment System, announced she will step down effective February 13, citing personal health reasons. Rountree was appointed in September 2025 by Governor Katie Hobbs.Ìý
Florida
Florida Submits Request for New Five-Year IMD Section 1115 Demonstration. The Centers for Medicare & Medicaid Services (CMS) on February 3, 2026, that Florida hasÌýsubmittedÌýan applicationÌýfor a new five-year Institutions for Mental Disease (IMD) Medicaid Section 1115 Demonstration. TheÌýstateÌýseeks authority to cover services forÌýMedicaid-enrolledÌýindividualsÌýresidingÌýin IMDsÌýwho are diagnosedÌýwith serious mental illness, serious emotional disorder, or substance use disorder, including substance abuse detoxification, recovery support services, and psychiatric treatment.ÌýEligible individuals would include those enrolled in the Statewide Medicaid Managed Care program.ÌýCMS will accept public commentsÌýthroughÌýMarch 5, 2026.
Indiana
Indiana to Issue RFP for All Medicaid Managed Care Programs in August 2026. The Indiana Family and Social Services Administration (FSSA)  on January 29, 2026, thatÌýanticipatesÌýreleasing a request for proposals (RFP)Ìýin August 2026ÌýforÌýthe state’sÌýfour Medicaid managed care programs—Healthy Indiana Plan, Hoosier Healthwise, Hoosier Care Connect, and Pathways for Aging. The programs cover approximately 1.4 million enrollees,Ìýand the procurement is estimated to be worthÌý$68 billion.Ìý
Michigan
Michigan Cancels Medicaid Behavioral PIHP Procurement. Bridge Michigan  on January 30, 2026, that Michigan has canceled its effort to restructure administration ofÌý$4.9 billionÌýin Medicaid-funded specialty behavioral health services forÌý300,000 individualsÌýwith serious mental illness, substance use disorders, and developmental disabilities. The Michigan Department of Health and Human Services ended the Prepaid Inpatient Health Plan (PIHP) rebid following lawsuits from regional providers and a court ruling that the plan violated state law by undercutting funding for Community Mental Health Service Programs. The procurement would have also reduced the current 10 behavioral health regions to three and introduced public-private partnerships to the system. The move leaves the current regional system in place for now and adds uncertainty around future reforms amid broader federal funding pressures.Ìý
Minnesota
MinnesotaÌýLaunches Medicaid Provider Revalidation Push. The Minnesota Department of Human Services  on February 2, 2026,ÌýthatÌýit has launched a statewide effort to revalidate more than 5,800 Medicaid providers in 13 high-risk service areas through unannounced site visits and expanded reviews. The initiative aims to address concerns raised by the Centers for Medicare & Medicaid Services (CMS), which plans to withhold more thanÌý$2 billionÌýannually in federal Medicaid funding unless Minnesota strengthens its fraud prevention controls. State Medicaid Director John Connolly said the effort includes staff redeployment, enhanced oversight, and new analytics tools to improve program integrity and restore federal confidence.Ìý
Washington
WashingtonÌýState of Reform Health Policy Conference: Making Connections for Affordability. On January 8, 2026,ÌýStateÌýof Reform (SOR), an ºìÁì½í¹Ï±¨ company,ÌýconvenedÌýits annual Washington State . More than 600 attendees from across the health and human services landscapeÌýparticipated, including representatives of state agencies, health systems and providers, payers, tribes, and community- basedÌýorganizations.Ìý
The conference provided a policy and action-orientated forum for discussing emerging challenges and opportunities in Washington’s healthcare system, with a particular focus on affordability, strengthening coverage and access, and cross-sector collaboration.Ìý
Key ThemesÌý
AffordabilityÌýwasÌýcentralÌýto many discussionsÌýthroughout the conference. Participants discussed state level policy efforts designed to mitigate rising healthcare costs and improve financial protection for consumers. This included Washington’s continued implementation of Senate Bill 5083, whichÌýestablishedÌýupdated reimbursement requirements for insurers covering public employees. Speakers also highlighted initiatives underway at the Office of the Insurance Commissioner and Washington Healthplanfinder intended to stabilize insurance markets and preserve Cascade Care premium subsidies.Ìý
A second core theme involved enhancing the accessibility and quality of care across health and social service systems. Washington leaders described ongoing work to reduce administrative burden for providers, including a coalition of payers and health systems to streamline prior authorization requirements.ÌýAttendees also examined access challenges in behavioral health, focusing on how upcoming investments in behavioral health infrastructure expansion and anticipatedÌýpayment-rateÌýlegislation may support improved quality, system capacity, and care coordination across the continuum.Ìý
In addition, throughout the conference, collaboration was a central theme. Attendees shared examples of partnerships that are working and identified opportunities for new initiatives across state agencies, industry partners, community organizations, and tribal governments. Ìý
StateÌýof Reform hosts health policy conferences across 11 markets each year. The next event will take place in  on April 15, 2026. To view the full conference schedule, visit the .Ìý
Private Market News
Fueled By
No Surprises Disputes Increasing Even as Arbiters Catch Up, CMS Says
TheÌýCenters for Medicare & Medicaid Services (CMS)Ìýreleased new data on independent dispute resolution in the first half of 2025.ÌýRoughly 1.2Ìýmillion cases were filed in that period, mostly by the same private equity-backed providers.ÌýIn the first half of 2025, the top 10 initiating parties accounted forÌýnearly 70ÌýpercentÌýof all disputes, withÌýHaloMD, Team Health, and SCP Health aloneÌýrepresentingÌý44Ìýpercent. Providers prevailed in 88ÌýpercentÌýof resolved cases and wereÌýfrequentlyÌýpaid three to four times above comparable in-network rates, highlighting cost challenges for insurers.
Our Insights
Fueled By Experts Across Our ºìÁì½í¹Ï±¨ Companies
ºìÁì½í¹Ï±¨
Medicaid Changes in the OBBBA and Implications for the Marketplace and Individual Market in 2027
In recent years, the individual market has undergone significant disruption. TheÌýexpirationÌýof enhanced premium tax credits (ePTC) at the end of 2025 and sweeping eligibility changes under the 2025 Budget Reconciliation Act (OBBBA) have reshaped—and will continue to reshape—the individual market.ÌýThis brief explores how these coming changes will reshape coverage pathways and costs, and examines implications for consumer affordability and churn, issuer pricing and risk pools, and state administrative burdens—alongside strategies for states, issuers, and policymakers to mitigate adverse effects.
CMS ACCESS Model: A New On-Ramp to Outcomes-Based, Tech-Enabled Care in Traditional Medicare
The Centers for Medicare & Medicaid Services (CMS) Innovation Center recently published applications for its new  (Advancing Chronic Care with Effective, Scalable Solutions), a 10-year voluntary initiative beginning July 2026. The model is designed to advance outcomes-based, technology-enabled care delivery in Original Medicare and aligns with the Innovation Center’s priorities of strengthening prevention, empowering beneficiaries, and promoting performance-based competition. This article summarizes the model’s design, highlights key considerations for prospective applicants, and addresses common questions our Medicare and technology experts fielded during a recent Health Management Associates (ºìÁì½í¹Ï±¨)/Leavitt Partners webinar. Ìý
Wakely
ACCESS Model Implications for Care Management Vendors
On December 1, 2025, the Centers for Medicare & Medicaid Services (CMS) announced the creation of the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model. ACCESS is designed to expand access to technology-supported solutions that enable providers to improve outcomes for patients with chronic conditions. The model is scheduled to begin July 1, 2026, with applications no later than April 1, 2026. This paper outlines the ACCESS model, conditions for vendor participation, and the implications—both opportunities and challenges— for care management vendors operating in or seeking entry into Traditional MedicareÌý
2025 Individual Market Risk Pool Considerations Updated
In this paper, Wakely consultants updateÌýpriorÌýanalysisÌýon 2025 individual market risk pool considerations. This updated version includes data through October 2025. Results indicateÌýan overall increase in normalized relative risk in 2025 from 2024.
Webinar: CMMI’s GUARD Model: Drug Scope, Geographic Design, and Implications for Medicare Part D Plans
On February 11, WakelyÌýconsultantsÌýwill hostÌýa webinarÌýintended for Medicare Part D plan leaders, actuaries, pharmacy and rebate strategy teams, policy and compliance professionals, and health plan executivesÌýseekingÌýto understand the practical implications of the proposed GUARD Model.
Webinar: Summary & Impacts of the 2027 Medicare Advantage Advance Notice
The Centers for Medicare & Medicaid Services (CMS) recently released the 2027 Advance Notice of Methodological Changes for Medicare Advantage Capitation Rates and Part C/D Payment Policies, which proposesÌýimportant changesÌýin plan payments, riskÌýadjustmentÌýand other key financial and regulatory requirements for 2027.ÌýOnÌýFebruary 12,Ìý2026, joinÌýconsultantsÌýfromÌýWakely, an ºìÁì½í¹Ï±¨ company, forÌýan overview of the proposed changes, with an emphasis on theÌýlikely impactÌýthat the new rates and policies will have on Medicare Advantage bids, membership growth,ÌýqualityÌýand strategy. Speakers will also touch on the important items from the CY2027 Proposed Rule, released on 11/25/2025.
Webinar: CY2026 Trends in Medicare Advantage Part D Plan Benefits
On February 25, 2026,Ìýjoin the experts from Wakely, an ºìÁì½í¹Ï±¨ Company, for a data-driven discussion of the key Part D benefit trends shaping Medicare Advantage Part D plans in CY2026. The Inflation Reduction Act’s Part D benefit redesignÌýcommencedÌýJanuary 1, 2025, with Maximum Fair Price drugs introduced January 1, 2026. As benefit design becomes more uniform across Part D plans, thisÌýwebinarÌýexplores how sponsors adjusted the Part D benefits of their plans to meet the requirements of the legislation, whileÌýstillÌýremainingÌýcompetitive. We will review the CY2025->CY2026 movements of Part D benefits and formulary placement, in addition to exploring benefit & formulary differences between MAPD & PDP plans for CY2026.Ìý
Webinar Replay
Redefining Revenue: Building Financial Resilience in an Era of Policy and Payment Change
Watch HereRFP Calendar
RFP Calendar
| Date | State/Program | Event | Beneficiaries |
|---|---|---|---|
| Date: February 2026 | State/Program: Illinois | Event: Awards | Beneficiaries: 2,400,000 |
| Date: February 17, 2026 | State/Program: Nevada CO D-SNP | Event: Proposals Due | Beneficiaries: 88,000 |
| Date: February 19, 2026 | State/Program: Nevada Children's Specialty | Event: Awards | Beneficiaries: NA |
| Date: May 12, 2026 | State/Program: Nevada CO D-SNP | Event: Awards | Beneficiaries: 88,000 |
| Date: June 24, 2026 | State/Program: Wisconsin LTC GSR 3 | Event: Awards | Beneficiaries: 56,000 (all GSR) |
| Date: August 2026 | State/Program: Indiana | Event: RFP Release | Beneficiaries: 1,400,000 |
| Date: January 1, 2027 | State/Program: Illinois | Event: Implementation | Beneficiaries: 2,400,000 |
| Date: January 1, 2027 | State/Program: Nevada Children's Specialty | Event: Implementation | Beneficiaries: NA |
| Date: January 1, 2027 | State/Program: Nevada CO D-SNP | Event: Implementation | Beneficiaries: 88,000 |
| Date: January 1, 2027 | State/Program: Wisconsin LTC GSR 3 | Event: Implementation | Beneficiaries: 56,000 (all GSR) |
| Date: January 1, 2027 | State/Program: Illinois Tailored Care Management Program | Event: Implementation | Beneficiaries: 22,400 |
| Date: January 1, 2028 | State/Program: Wisconsin LTC GSR 4,6 | Event: Implementation | Beneficiaries: 56,000 (all GSR) |
| Date: Fall 2027 | State/Program: Oregon | Event: RFP Release | Beneficiaries: 1,200,000 |
| Date: 2028 | State/Program: North Carolina | Event: RFP Release | Beneficiaries: 2,200,000 |